Subtype variability, virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola

Journal of Antimicrobial Chemotherapy

Volumn 61, Issue 3, 2008, Pages 694-698

  Garrido, Carolina ^a   Zahonero, Natalia ^a   Fernándes, Diana ^b   Serrano, Dulcelina ^c   Silva, Ana Rita ^b   Ferraria, Nelia ^b   Antúnes, Francisco ^b   González Lahoz, Juan ^a   Soriano, Vincent ^a   de Mendoza, Carmen ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL DE SANTA MARIA   (Portugal)

^c Hospital Esperança   (Angola)

Author keywords

DBS; HIV subtypes; Non B subtypes; Viral load

Indexed keywords

EFAVIRENZ; GLYCOPROTEIN GP 41; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; NEVIRAPINE; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ADULT; ANGOLA; ANTIBIOTIC RESISTANCE; ARTICLE; BLOOD SAMPLING; BLOOD TRANSFUSION; CD4 LYMPHOCYTE COUNT; FEMALE; GENETIC VARIABILITY; HETEROSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NONHUMAN; RETROSPECTIVE STUDY; TREATMENT DURATION; VIREMIA; VIRUS MUTATION; VIRUS RESISTANCE; VIRUS TRANSMISSION;

ADULT; ANGOLA; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; RETROSPECTIVE STUDIES;

EID: 40049096325     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkm515     Document Type: Article

References (11)

1. McCutchan F. Global epidemiology of HIV. J Med Virol 2006; 78 Suppl 1: 7-12.
2. Holguin A, Hertogs K, Soriano V. Performance of drug resistance assays in testing HIV-1 non-B subtypes. Clin Microbiol Infect 2003; 9 323-6.
3. Weidle S, Malamba R, Mwebaze C et al. Assessment of a pilot antiretroviral drug therapy programme in Uganda: Patients' response, survival, and drug resistance. Lancet 2002; 360: 34-40.
4. Geretti AM. HIV-1 subtypes: Epidemiology and significance for HIV management. Curr Opin Infect Dis 2006; 19: 1-7.
5. Perrin L, Kaise L, Yerly S. Travel and the spread of HIV-1 genetic variants. Lancet Infect Dis 2003; 3: 22-7.
6. De Mendoza C, Koppelman M, Montes B et al. Multicenter evaluation of the Nuclisens EasyQ HIV-1 v1.1 assay for the quantitative detection of HIV-1 RNA in plasma. J Virol Methods 2005; 127: 54-9.
7. Garrido C, Zahonero N, Soriano V et al. Correlation between HIV-1 viral load quantification measured in dried blood spots (DBS) and plasma using two commercial assays. Conference on Retroviruses & Opportunistic Infections, Boston, 3-6 February 2008 [abstract U-161] (in press).
8. Steinbrook R. Message from Toronto - Deliver AIDS treatment and prevention. N Engl J Med 2006; 355: 1081-4.
9. Abecasis A, Paraskevis D, Epalanga M et al. HIV-1 genetic variants circulation in the North of Angola. Infect Genet Evol 2005; 5 231-7.
10. Masciotra S, Garrido C, Youngpairoj A et al. High concordance between HIV-1 drug resistance genotypes generated from plasma and dried blood spots in treated persons. AIDS 2007; 21: 2503-12.
11. Eshleman S, Becker-Pergola G, Deseyve M et al. Impact of HIV-1 subtype on women receiving single-dose nevjrapine prophylaxis to prevent HIV-1 vertical transmission (HIV Network for prevention trials 012 study). J Infect Dis 2001; 184: 914-7.